Sangamo Therapeutics (SGMOQ) Net Cash Flow (2010 - 2025)

Sangamo Therapeutics' Net Cash Flow history runs 16 years deep, the most recent figure standing at -$9.6 million for Q4 2025.

• On a quarterly basis, Net Cash Flow fell 293.8% year-over-year to -$9.6 million in Q4 2025; TTM through Dec 2025 was -$26.6 million, a 2045.48% decrease from a year earlier, with the FY2025 full-year figure at -$26.6 million, down 2045.48% from the prior year.
• Net Cash Flow retreated to -$9.6 million in Q4 2025 per SGMOQ's latest filing, from -$9.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $46.8 million in Q2 2021 and bottomed at -$58.8 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$8.7 million (2021), against an average of -$5.8 million.
• Across the five-year window, Net Cash Flow plunged 633.08% in 2022 and surged 220.71% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $2.0 million in 2021, then surged by 150.81% to $5.1 million in 2022, then sank by 348.34% to -$12.7 million in 2023, then jumped by 139.2% to $5.0 million in 2024, then plunged by 293.8% to -$9.6 million in 2025.
• Per Business Quant, the three latest SGMOQ Net Cash Flow figures stand at -$9.6 million (Q4 2025), -$9.4 million (Q3 2025), and $10.4 million (Q2 2025).